🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

So much gratitude to have Sir Mel Greaves as a constant guiding light. Since my PhD, a mentorship relationship that lasts through decades. His evolutionary principles have guided my study design & interpretation. Every time we meet I leave in awe & inspired. A true knight! 🙏🏼Mel

Hanging out with some of the very best SocforHemepath #USCAP2025 Plus today I found out that dreams do come true... looking forward to a trully unifed classification for heme malignancies in the next WHO 📘 Let's get this done right this time!

BIG NEWS!

👇me and Elli Papaemmanuil, PhD with front row seats at packed Edwin Cuppen / Hartwig Medical-organized clinical cancer genome conference, rapt as Charles Swanton keynote unpacks ~5-10 years worth of unpublished data from his lab to basically solve never-smoker lung cancer 😮😲🙀🤯

As a co-founder of 23andMe, with all the recent news I felt it was time to express my views on the company, after witnessing the downfall of an idea and brand that could have become the world’s leading digital health platform. The idea for 23andMe came to me after years working

Coming back home, New York you are a city like no other 💛

Excited to share our paper out today in Cell Press discovering RNA mis-splicing derived neoantigens & their cognate T cell receptors (TCRs) as well as characterization of endogenous neoantigen T cells in leukemia patients. authors.elsevier.com/sd/article/S00…

Tumor infiltrating clonal hematopoiesis associated with poor outcomes in solid tumors. Wonder if this is how IL1B inhibition seemed to improve survival from cancer in CANTOS… nejm.org/doi/full/10.10…

Some trully trainee led science! Elsa Bernard Oriol Pich Maria Zagorulya - our work is done here! Read how CH can influence solid tumor progression & treatment response ⬇️ NEJM with the one & only Charles Swanton Memorial Sloan Kettering Cancer Center The Crick

It has been unclear why cancer patients with CH have worse outcomes. Our work published NEJM uncovers that Tumor infiltrating CH (TI-CH) has a direct role in immune remodelling of the TME with implications for tumor progression & treatment response. Memorial Sloan Kettering Cancer Center The Crick

Congratulations to Memorial Sloan Kettering Cancer Center MSK-IMPACT team and OncoKB™ for receiving the #AACR25 TEAM Science Award! The impact of this team, assay & data to our understanding of cancer biology is unprecedented.

TP53 mutated AML…. surrounded by all of our failed therapies ….. #hemepath

Phenotyping recurrent genomic architectures. Led by Maria Sirenko Soobeom Lee & Z. Sun, our study Cell Stem Cell shows how patterns of co-mutations shape lineage composition + drive diverse cellular programs in AML. Awesome collaboration with Dan Landau Iannis Aifantis++🧵⬇️

On the eve of #ASCO25, it's #AcuteMyeloidLeukemia Thursday. Here are Top Posts of the Week! 🎉🎉🎉 1/ Elli Papaemmanuil, PhD on how patterns of co-mutations shape lineage composition + drive diverse cellular programs in AML: x.com/PapaemmanuilLa…

🚨🚨Paper out! 🚨🚨 Delighted to share our work, now published in Nature Genetics 🧬! shorturl.at/94s5S We identified a targetable, chromothripsis-associated genetic event in blast phase (BP) MPN, a particularly poor prognostic subtype of acute leukaemia. 1/n 🧵👇

Excited to share our latest study, led by Curtis Lachowiez & Sanam Loghavi, MD صنم لغوی 🔬🧬 on the relevance of data informed metrics in setting guidelines for disease classification in myeloid neoplasms.